迈向单核细胞HLA-DR床旁监测:一项概念验证研究
本研究开发了一种简化的全血一步法流式细胞术方案,用于测量单核细胞HLA-DR表达,该方案整合了红细胞裂解、抗体和固定试剂。在连续两个脓毒症休克患者队列(共n=37)中,该方案与标准化常规方案进行了比较。第一队列24例中两法强相关;加入低剂量甲醛优化后,第二队列13例中仍强相关。指尖采血与静脉穿刺样本结果相似,证明床旁检测的可行性。
要点
- 一步法全血流式细胞术方案可在床旁测量脓毒症休克患者单核细胞HLA-DR,与常规方案强相关。
- 在24例脓毒症休克患者中,一步法与常规方案强相关;加入低剂量甲醛优化后,第二队列13例中仍强相关。
- 指尖采血与静脉穿刺样本提供的单核细胞HLA-DR结果相似。
- 该床旁方案有助于克服既往限制该生物标志物在ICU广泛使用的分析前约束。
适用人群与场景
- 脓毒症休克患者(两个连续队列,共n=37)
- 重症患者(概念验证中应用于少数受试者的床旁场景)
处置流程与药物剂量
- 一步法方案:全血样本,包含红细胞裂解、抗体和固定试剂,一步完成。
- 优化方案:在染色和裂解溶液中加入低剂量甲醛作为稳定剂。
- 床旁场景:通过指尖采血收集毛细血管血。
研究设计与关键结果
- 研究类型:概念验证研究,开发并验证一步法流式细胞术方案。
- 第一队列24例脓毒症休克患者:一步法与常规方案强相关。
- 优化方案(加入低剂量甲醛)在第二队列13例患者中测试,与常规方案仍强相关。
- 指尖采血与静脉穿刺样本结果相似。
证据类型、等级与局限
- 证据类型:概念验证研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,本研究证明了对重症患者进行床旁流式细胞术测量单核细胞HLA-DR的可行性,有助于克服既往限制该生物标志物在ICU广泛使用的分析前约束。
- 作者认为,指尖采血样本的初步结果是有前景的。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Decreased expression of human leukocyte antigen-DR on monocytes (mHLA-DR) is recognized as the most appropriate marker for the monitoring of immune alterations in septic patients and critically ill subjects. Its measurement has been established for years by flow cytometry, but remains under-used due to pre-analytical constraints. The objectives of the present work were to develop a rapid and robust one-step protocol.
METHODS: A novel, simplified protocol has been developed to measure mHLA-DR in whole blood using flow cytometry. It is a one-step procedure that includes red cell lysis, antibodies, and fixative reagents. It has been compared to the standardized routine protocol in two consecutive cohorts of septic shock patients (n = 37). Finally, the protocol was applied to a few subjects in point-of-care settings, by collecting capillary blood from fingerpricks.
RESULTS: Strong correlation was observed between the one-step method and routine protocol in 24 patients. After testing several stabilizing agents, the procedure was further optimized by adding a low-dose formaldehyde to the stain and lyse solution. This improved method was tested in a second cohort of 13 patients, and again strongly correlated to the routine protocol. Finally, the fingerprick and venous puncture samples were shown to provide similar results.
CONCLUSIONS: The present work demonstrates the feasibility of a bedside protocol for flow cytometry measurement of mHLA-DR in critically ill subjects. This helps overcome pre-analytical constraints previously identified, which have limited wider use of this biomarker in intensive care units. In addition, preliminary results from fingerprick samples are promising.
参考来源
- Bourgoin P, Taspinar R, Gossez M, et al. Toward Monocyte HLA-DR Bedside Monitoring: A Proof-of-Concept Study. Shock. 2021. PMID: 33021570. doi:10.1097/SHK.0000000000001673
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。